Comparisons
Blends or Separate Vials: Fixed Ratios, Molar Arithmetic and Certificate Requirements
A co-formulated vial locks its composition at manufacture. Everything that follows — the maths, the certificate, the design freedom — comes from that.
Manufacture decides the ratio inside a blend; the experimenter decides it in a multi-vial stack. Every other difference, whether in certificate interpretation, concentration calculations or purity claims, flows from that single fact. Picking between blends and separate vials is a matter of study design before it is a matter of purchasing, and the category's most frequent mistake is handling a co-formulated vial as though it held one molecule. Below we describe the three formats, the ratio and molarity arithmetic a blend imposes, how a multi-component certificate must differ from a single-peptide one, and which format suits which purpose.
Three formats, not two
The contrast between the Wolverine blend and the Wolverine Stack makes the point: one is a single vial of BPC-157 and TB-500 co-lyophilized at a fixed 1:1 mass ratio, the other is three separately sealed vials of BPC-157, TB-500 and GHK-Cu, whose proportions you set yourself.
Interpreting the label
Blend labels give total mass and, where the split is unequal, the per-component breakdown. A vial marked 10 mg (5/5) holds 5 mg of each of two peptides. A vial marked simply 80 mg, as with the four-component KLOW Blend, leaves the certificate to reveal how those 80 mg divide, and in most four-component preparations the split is not equal. Any blend whose documentation refuses to state per-component mass cannot be used quantitatively.
Working out concentration per component
- Begin with the blend. Reconstituting a 10 mg (5/5) Wolverine vial in 2 mL of diluent gives 10 ÷ 2 = 5 mg/mL of total peptide.
- Divide it. Since the vial holds 5 mg of BPC-157 and 5 mg of TB-500, the solution is 2.5 mg/mL of each rather than 5 mg/mL of either.
- Per graduation. One unit on a U-100 syringe, 0.01 mL, holds 25 mcg of BPC-157 plus 25 mcg of TB-500. A 0.1 mL withdrawal gives 250 mcg of each, 500 mcg in total.
- Against separate vials. Reaching the same 2.5 mg/mL of each from single vials means reconstituting 5 mg of BPC-157 in 2 mL and 5 mg of TB-500 in 2 mL: two reconstitutions and two septum entries per transfer, but the ability to change either concentration afterwards.
The mg/mL arithmetic beneath this is exactly what any vial requires and is covered in peptide reconstitution math explained.
Where equal mass misleads
This is the point that trips up experienced researchers. Equal masses give equal moles only when the components share a molecular weight, which they seldom do.
- BPC-157 weighs 1,419.55 Da, so 2.5 mg/mL means 2.5 g/L ÷ 1,419.55 g/mol = 1.76 mM.
- TB-500 weighs 889.02 Da, so 2.5 mg/mL means 2.5 ÷ 889.02 = 2.81 mM.
Identical masses therefore supply roughly 1.6 times as many TB-500 molecules as BPC-157 molecules. For questions of receptor occupancy or stoichiometry that is the figure that counts, and a fixed-mass blend offers no way to correct it. Designs requiring equimolar components require single vials.
Requirements for a blend certificate
A single-peptide certificate carries one HPLC purity value and one mass-spectrometry identity confirmation. No blend can be summarised that way, so honest documentation looks different:
- Purity per component, determined before blending. Each peptide should be synthesised, purified and released against its own certificate before combination. "≥99% purity" on a blend normally means every input met that specification, not that the mixture yields one 99% peak.
- A chromatogram that separates the components. Under reversed-phase conditions, four peptides of differing hydrophobicity elute at four retention times, so a blend chromatogram should display the expected peak count with the expected area ratios. One broad peak is a warning sign.
- Per-component mass in the vial, determined gravimetrically at fill or by quantitative amino acid analysis.
- Identity confirmation for every component, since a blend has several molecular weights and MS should account for all of them.
The general framework for reading such documents is in how to read a peptide COA. Where a supplier's blend certificate offers a single purity number and one mass with no per-component detail, the document is not describing the product.
Matching format to purpose
Reach for a blend when
- The protocol fixes a ratio you have no intention of changing, as with CJC-1295 + Ipamorelin, where two secretagogues act at different receptors on one cell and the pairing is the established research configuration.
- Handling steps contribute meaningful error. Each reconstitution brings pipetting variance, a septum puncture and a contamination risk, and a four-component blend removes three of each.
- Cost per milligram of material matters and the supplied ratio is acceptable.
Reach for separate vials when
- One component must be varied against the others, the defining feature of a concentration-response design.
- The comparison has to be equimolar rather than equal-mass.
- Components differ substantially in stability. Copper peptides, methionine-bearing sequences and disulfide-bonded peptides degrade on different schedules, and once co-formulated in solution the whole vial is governed by its weakest member.
- Lot traceability per component is needed for publication or internal quality control.
- Components require different diluents or pH ranges to dissolve properly.
The NAD+ Longevity Stack typifies the second list: three individually sealed vials sold as a kit and reconstituted independently.
Frequent errors
- Reading total vial mass as per-component mass. An 80 mg four-component vial holds 80 mg of nothing in particular.
- Presuming an equal split when the label says nothing about one.
- Quoting molar concentrations for a blend without recalculating each component against its own molecular weight.
- Accepting one purity figure for a multi-component vial.
- Trying to split a blend to recover a single component. Once co-lyophilized, separation demands preparative chromatography; if you need one peptide alone, buy it alone from the lyophilized vial range.
The complete co-formulated and multi-vial range is in peptide blends and stacks.
Questions
What is meant by "10 mg (5/5)" on a label?
The vial holds 10 mg of peptide in total, divided as 5 mg of each of two components. Reconstituted in 2 mL of diluent it gives 5 mg/mL overall but 2.5 mg/mL of each component, and the latter is what belongs in your calculations.
Does a 1:1 blend contain equal moles?
Only by chance. Equal masses are equimolar solely when both peptides weigh the same. BPC-157 is 1,419.55 Da and TB-500 is 889.02 Da, so 2.5 mg/mL of each yields 1.76 mM and 2.81 mM respectively, about 1.6 times more TB-500 molecules. Equimolar designs need separate vials.
What must a blend certificate report?
Purity for each component measured before blending, a chromatogram separating every component at its own retention time with the expected area ratios, the mass of each component in the vial, and mass-spectrometry identity confirmation for every molecular weight present. One purity value and one mass cannot describe a multi-component product.
Can a blend be taken apart again?
Not in practice. Separating co-lyophilized components requires preparative chromatography and a re-purification workflow. If a study needs a single peptide, order that peptide on its own rather than trying to fractionate a blend.
In which situations is a blend preferable?
When the protocol uses a fixed ratio that will not change, when handling steps add meaningful variance, and when the components are stable in each other's company. Every reconstitution avoided removes a pipetting error, a septum puncture and a contamination opportunity, which counts for a lot in a four-component preparation.
When are separate vials the better option?
Whenever one component is varied against the others, whenever the comparison must be equimolar rather than equal-mass, whenever the components differ appreciably in stability, whenever per-component lot traceability is required, and whenever different diluents or pH ranges are needed for clean dissolution.
What distinguishes a stack from a blend?
A stack supplies several individually sealed and individually tested vials as one catalogue item at a kit price. Nothing is co-formulated, so every vial has its own certificate and can be reconstituted to its own concentration. Only the pricing is bundled, not the chemistry.
Do blends degrade more quickly than single vials?
They can once in solution. When components share a vial, the working life of the whole preparation is dictated by its least stable member, and copper complexes, methionine-containing sequences and disulfide-bonded peptides all decay on different timescales. Lyophilized and frozen, the gap is much narrower.